The role of users in innovation in the pharmaceutical industry

Drug Discovery Today

Volumn 13, Issue 7-8, 2008, Pages 353-359

  Smits, Ruud E H M ^a   Boon, Wouter P C ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

TRASTUZUMAB;

DRUG INDUSTRY; DRUG USE; HEALTH INSURANCE; MEDICAL SOCIETY; MODEL; POLICY; REIMBURSEMENT; REVIEW;

CONSUMER PARTICIPATION; DRUG INDUSTRY; HEALTH POLICY; HUMANS; ORGANIZATIONAL INNOVATION;

EID: 41549120233     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2007.12.006     Document Type: Review

References (64)

1. Nelson R., and Winter S. In search of a useful theory of innovation. Res. Policy 6 (1977) 36-76
2. Rip A. Wetenschap als Mensenwerk. Over de Rol van Natuurwetenschappen in de Samenleving (1978), AMBO
3. Bijker W., et al. The Social Construction of Technological Systems. New Directions in the Sociology and History of Technology (1987), MIT Press
4. Etzkowitz H., and Leydesdorff L. The dynamics of innovation: from National Systems and "mode 2" to Triple Helix of university-industry-government relations. Res. Policy 29 (2000) 109-123
5. Ziman J. Real Science: What it is, and What it Means (2001), Cambridge University Press
6. Gibbons M., et al. The New Production of Knowledge. The Dynamics of Science and Research in Contemporary Societies (1994), Sage Publications
7. OECD. Technology and the Economy. The Key Relationships (1992), OECD
8. Rip A., and Kemp R. Technological change. In: Rayner S., and Malone E.L. (Eds). Human Choice and Climate Change Vol. 2 (1998), Battelle Press 327-399
9. Dosi G., et al. Technical Change and Economic Theory (1988), Pinter
10. Smits R., and Kuhlmann S. The rise of systemic instruments in innovation policy. Int. J. Foresight Innovation Policy 1 (2004) 4-32
11. Freeman C., and Lundvall B.A. Small Countries Facing the Technological Revolution (1988), Pinter Publishers Ltd
12. Lundvall B.A. National Systems of Innovation: Towards a Theory of Innovation and Interactive Learning (1992), Pinter Publishers
13. Nelson R. National Innovation Systems (1993), Oxford University Press
14. Freeman C. The diversity of national research systems. In: Barré R., et al. (Ed). Science in Tomorrows Europe (1997), Economica International
15. Smits R. The new role of strategic intelligence. In: Tübke A. (Ed). Strategic Policy Intelligence: Current Trends, the State of Play and Perspectives, IPTS Technical Report Series (2002), IPTS
16. Kuhlmann S., et al. Improving Distributed Intelligence in Complex Innovation Systems (1999), Fraunhofer ISI
17. Chesbrough H.W. Open Innovation: The New Imperative for Creating and Profiting from Technology (2003), Harvard Business School Press
18. Munos B. Can open-source R&D revigorate drug research?. Nat. Rev. Drug Discov. 5 (2006) 723-729
19. Radisch J. More medicines for neglected and emerging infectious diseases. Bull. WHO 85 (2007) 572
20. Schmid E.F., and Smith D.A. Is pharmaceutical R&D just a game of chance or can strategy make a difference?. Drug Discov. Today 9 (2004) 18-26
21. Maxwell R.A. The state of the art of the science of drug discovery - an opinion. Drug Dev. Res. 4 (1984) 375-389
22. Vastag B. New clinical trials policy at FDA. Nat. Biotechnol. 24 (2006) 1043
23. Ghofrani H.A., et al. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat. Rev. Drug Discov. 5 (2006) 689-702
24. Arlington S. What will pharma look like in 2020?. Drug Discov. World 8 (2007) 9-16
25. Ashburn T.T., and Thor K.B. Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 3 (2004) 673-683
26. Hara T. Innovation in the Pharmaceutical Industry (2003), Edward Elgar
27. Ford N., et al. Discussions in Geneva, demonstrations in Delhi: why incentives for drug innovation need reviewing. Drug Discov. Today 12 (2007) 349-351
28. Von Hippel E. Democratizing Innovation (2005), MIT Press
29. Porter M.E. The Competitive Advantage of Nations (1990), Free Press
30. Oudshoorn N., and Pinch T. How Users Matter - The Co-construction of Users and Technology (2003), The MIT Press
31. Smits R., and Den Hertog P. TA and the management of innovation in economy and society. Int. J. Foresight Innovation Policy 3 (2007) 28-52
32. WHO. Priority Medicines for Europe and the World (2004), World Health Organization
33. Nelis A. DNA Diagnostics in the Netherlands (original title: 'DNA-diagnostiek in Nederland') (1998), Twente University Press
34. Caron-Flinterman J.F., et al. The experiential knowledge of patients: a new resource for biomedical research?. Soc. Sci. Med. 60 (2005) 2575-2584
35. Wadman M., and Abbott A. A long week in stem-cell politics. Nature 442 (2006) 335
36. Rabeharisoa V. The struggle against neuromuscular diseases in France and the emergence of the "partnership model" of patient organisation. Soc. Sci. Med. 57 (2003) 2127-2136
37. Epstein S. The construction of lay expertise: AIDS activism and the forging of credibility in the reform of clinical trials. Sci. Technol. Hum. Values 20 (1995) 408-437
38. Bazell R. Her-2: The Making of Herceptin, A Revolutionary Treatment for Breast Cancer (1998), Random House
39. Terry S.F., et al. Advocacy groups as research organizations: the PXE International example. Nat. Rev. Genet. 8 (2007) 157-163
40. RGO. Advies Orphan Drugs (weesgeneesmiddelen) (1998), Raad voor Gezondheidsonderzoek
41. Bower J. From the 'rhetoric of hope' to the 'patient-active paradigm' - strategic positioning of pharmaceutical and biotechnology companies. Technol. Anal. Strateg. Manage. 17 (2005) 183-204
42. O'Doherty D., and Arnold K. Understanding Innovation: The Need for a Systemic Approach (2003), IPTS
43. Milstien, J.B. et al. (2005) Vaccines and drugs: characteristics of their use to meet public health goals. The World Bank Health, Nutrition and Population (HNP) Discussion Paper
44. Office of Technology Assessment at the German Bundestag. Pharmacogenetics - Status Report Within the Framework of Monitoring "Genetic Therapy, Genetic Diagnosis" (2005), Office of Technology Assessment at the German Bundestag
45. Lyngstadaas A. Status and potential of gene therapy in clinical medicine - assessment of an emerging health technology through systematic survey of clinical gene therapy protocols and published results. Int. J. Technol. Assess. Health Care 18 (2002) 645-674
46. Gijsbers G., et al. Biotechnology in 2030 - Four Scenarios (2007), The Netherlands Commission on Genetic Modification (COGEM)
47. Porter A.L., et al. Technology futures analysis: toward integration of the field & new methods. Technol. Forecasting Soc. Change 71 (2004) 287-303
48. Broerse J.E.W., and Bunders J.F.G. Requirements for biotechnology development: the necessity of an interactive and participatory innovation process. Int. J. Biotechnol. 2 (2000) 275-296
49. Grin J. Vision assessment to support shaping 21st century society? Technology assessment as a tool for political judgement. In: Grin J., and Grunwald A. (Eds). Vision Assessment: Shaping Technology in 21st Century Society - Towards a Repertoire for Technology Assessment (2000), Springer
50. Guston D., and Sarewitz D. Real-time technology assessment. Technol. Soc. 24 (2002) 93-109
51. Kuwahara, T. (2005) Results of the Sixth Technology Forecast Survey - Future Technology in Japan Toward The Year 2025 - NISTEP Report No. 52, NISTEP
52. Miles I. UK Foresight: three cycles on a highway. Int. J. Foresight Innovation Policy 2 (2005) 1-34
53. Academy of Finland and Tekes. Finsight 2015. The Outlook of Science, Technology and Society (2007), Finnish Academy of Science
54. Roijakkers N., and Hagedoorn J. Inter-firm R&D partnering in pharmaceutical biotechnology since 1975: trends, patterns, and networks. Res. Policy 35 (2006) 431-446
55. Herxheimer A. Relationships between the pharmaceutical industry and patients' organisations. Br. Med. J. 326 (2003) 1208-1210
56. Van den Elst J., et al. Innovation in practice: Philips Applied Technologies. Int. J. Technol. Manage. 34 (2006) 217-231
57. Boon, W.P.C. et al. Demand articulation in intermediary organisations: the case of orphan drugs in the Netherlands. Technol. Forecasting Soc. Change (in press)
58. Duckenfield M., and Rangnekar D. The Rise of Patient Groups and Drug Development - Towards a Science of Patient Involvement (2004), University College London, School of Public Policy
59. Sanchez-Serrano I. Success in translational research: lessons from the development of bortezomib. Nat. Rev. Drug Discov. 5 (2006) 107-114
60. Blume S.S. The rhetoric and counter-rhetoric of a "bionic" technology. Sci. Technol. Hum. Values 22 (1997) 31-56
61. Nature Reviews Drug Discovery Editorial. A delicate balancing act. Nat. Rev. Drug Discov. 6 (2007) 685
62. Ferner R.E., and McDowell S.E. How NICE may be outflanked. Br. Med. J. 332 (2006) 1268-1271
63. Brown N., and Webster A. New Medical Technologies and Society (2004), Polity Press
64. Mintzes B., and Kent A. Should patient groups accept money from drug companies? Yes/No. Br. Med. J. 334 (2007) 934-935